Piramal Looks To Build On Pharma Growth
Q2 Results Show 17% Increase In Global Pharma Business
Piramal says it is looking to build on the 17% growth in its Global Pharma business reported in its financial second quarter by investing in manufacturing expansion across differentiated product areas.
You may also be interested in...
An FDA warning letter issued to Aurobindo highlights recurring failures over several sites, while Teva is setting up a biologics development campus in the US and Nexus is investing in sterile injectables capacity.
To boost the technology used in its digihaler family of inhalers, Teva has partnered with Amazon Web Services and Onica, a Rackspace Technology company. With this collaboration, Teva aims to protect patients’ information and ensure data security.
Catalent has announced the launch of a new technology, OptiGel DR, for the formulation and manufacture of delayed/enteric release softgels, offering advantages such as potentially enhancing bioavailability and reducing gastric reflux effects.